GeoVax Labs, Inc. has entered into a securities purchase agreement with healthcare-focused institutional investors for a registered direct offering expected to generate approximately $2.5 million in gross proceeds. The company will sell 3,968,256 shares of common stock and warrants to purchase up to 11,904,768 additional shares at a combined price of $0.63 per unit, with the warrants exercisable at the same price upon shareholder approval and expiring five years from that approval.
The funding comes at a critical juncture for the clinical-stage biotechnology company as it advances multiple therapeutic candidates. GeoVax intends to use the net proceeds to support research and development, manufacturing, clinical studies, and working capital requirements across its pipeline. This financial injection represents essential capital for maintaining momentum in clinical programs that target significant unmet medical needs.
Roth Capital Partners is serving as sole placement agent for the offering, which is expected to close on September 30, 2025, subject to customary closing conditions. The shares are being offered pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission. Investors can access detailed offering documents through the SEC's website at https://www.sec.gov, where electronic copies of the final prospectus supplement and accompanying prospectus will be available.
The importance of this funding extends beyond immediate financial stability. GeoVax's lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. These trials are evaluating the vaccine as a primary option for immunocompromised patients, including those with hematologic cancers, who may not respond adequately to currently authorized COVID-19 vaccines. The program also includes evaluation as a booster for chronic lymphocytic leukemia patients and as a more robust booster for healthy individuals previously vaccinated with mRNA vaccines.
In oncology, the company's Gedeptin® program has recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, representing a novel approach to solid tumor treatment. Additionally, GeoVax is developing a vaccine targeting Mpox and smallpox that, based on recent EMA regulatory guidance, may progress directly to Phase 3 clinical evaluation, bypassing earlier trial phases. The company maintains worldwide rights for its technologies and product candidates, with additional information available at https://www.geovax.com.
This financing round matters because it supports the development of specialized medical solutions for vulnerable patient populations. Immunocompromised individuals, including cancer patients, represent a significant demographic for whom current vaccine options may provide insufficient protection. The advancement of GeoVax's programs could lead to more effective prevention and treatment options for these high-risk groups, potentially reducing hospitalizations and improving quality of life for millions worldwide.
The biotechnology sector relies heavily on such capital infusions to sustain expensive clinical development processes. Successful advancement of these programs could not only benefit patients but also validate GeoVax's platform technologies, potentially opening doors for additional therapeutic applications. The company's progress in navigating regulatory pathways, particularly the potential direct progression to Phase 3 trials for its Mpox vaccine, demonstrates the evolving landscape of vaccine development and regulatory science.
